EGFR and neoplasm: At present, clinical trials have been performed on tumor types including, but not limited to, second-line squamous NSCLC (NCT03150875; ORIENT-3), first-line squamous NSCLC (NCT03629925; ORIENT-12), first-line non-squamous NSCLC (NCT03607539; ORIENT-11), and locally advanced epidermal growth factor receptor (EGFR)-mutated or metastatic non-squamous NSCLC (NCT03802240; ORIENT-31) previously treated with EGFR-tyrosine kinase inhibitor (30).